Article Text


  1. Xianhui Qin1,
  2. Jianping Li2,
  3. Yimin Cui3,
  4. Zeyuan Liu4,
  5. Zhigang Zhao5,
  6. Junbo Ge6,
  7. Deming Guan7,
  8. Jian Hu8,
  9. Yanni Wang9,
  10. Fumin Zhang10,
  11. Xin Xu11,
  12. Xiaobin Wang12,
  13. Xiping Xu1,
  14. Yong Huo2
  1. 1Institute of Biomedicine, Anhui Medical University, Hefei, China
  2. 2Department of Cardiology and Heart Center, Peking University First Hospital, Beijing, China
  3. 3Department of Pharmacy, Peking University First Hospital, Beijing, China
  4. 4Department of Pharmacy, First Affiliated Hospital of Academy of Military Medical, Sciences of China, Beijing, China
  5. 5Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  6. 6Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China
  7. 7Department of Cardiology, First Clinical Medical College of Harbin Medical University, Harbin, China
  8. 8Department of Cardiology, First Affiliated Hospital of China Medical University, Shenyang, China
  9. 9Department of Cardiology, First Affiliated Hospital of the Xian Jiaotong University, China
  10. 10Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China
  11. 11Guangdong Institute of Nephrology, Southern Medical University, Guangzhou, China
  12. 12Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, USA


    Objectives This study aimed to investigate if the homocysteine-lowering efficacy of two commonly used physiological doses (0.4 mg/d and 0.8 mg/d) of folic acid (FA) can be modified by individual methylenetetrahydrofolate reductase (MTHFR) C677T and/or methionine synthase (MTR) A2756G polymorphisms in hypertensive Chinese adults

    Methods A total of 480 subjects with mild or moderate essential hypertension were randomly assigned to three treatment groups: (1) enalapril only (10 mg, control group); (2) enalapril-FA tablet (10:0.4 mg (10 mg enalapril combined with 0.4 mg of FA), low FA group); and (3) enalapril-FA tablet (10:0.8 mg, high FA group), once daily for 8 weeks.

    Results After 4 or 8 weeks of treatment, homocysteine concentrations were reduced across all genotypes and FA dosage groups, except in subjects with MTR 2756AG/GG genotype in the low FA group at week 4. However, compared to subjects with MTHFR 677CC genotype, homocysteine concentrations remained higher in subjects with CT or TT genotype in the low FA group (p<0.05 for either of these genotypes) and TT genotype in the high FA group (p<0.05). Furthermore, subjects with TT genotype showed a greater homocysteine-lowering response than did subjects with CC genotype in the high FA group (mean percent reduction of homocysteine at week 8: CC 10.8% vs TT: 22.0%, p=0.005), but not in the low FA group (CC 9.9% vs TT 11.2%, p=0.989).

    Conclusions This study demonstrated that MTHFR C677T polymorphism can not only affect homocysteine concentration at baseline and post-FA treatment, but also can modify therapeutic responses to various dosages of FA supplementation.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.